500 related articles for article (PubMed ID: 22899803)
1. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model.
Freeman J; Marquis M; Crowther GS; Todhunter SL; Fawley WN; Chilton CH; Moeck G; Lehoux D; Wilcox MH
J Antimicrob Chemother; 2012 Dec; 67(12):2919-26. PubMed ID: 22899803
[TBL] [Abstract][Full Text] [Related]
2. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model.
Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2008 Nov; 62(5):1078-85. PubMed ID: 18772161
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model.
Chilton CH; Freeman J; Crowther GS; Todhunter SL; Wilcox MH
J Antimicrob Chemother; 2012 Oct; 67(10):2434-7. PubMed ID: 22723601
[TBL] [Abstract][Full Text] [Related]
4. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model.
Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2009 Mar; 63(3):520-5. PubMed ID: 19112083
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery.
Chilton CH; Freeman J; Baines SD; Crowther GS; Nicholson S; Wilcox MH
J Antimicrob Chemother; 2013 Sep; 68(9):2078-82. PubMed ID: 23759507
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection.
Freeman J; Baines SD; Jabes D; Wilcox MH
J Antimicrob Chemother; 2005 Oct; 56(4):717-25. PubMed ID: 16143709
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.
Crowther GS; Baines SD; Todhunter SL; Freeman J; Chilton CH; Wilcox MH
J Antimicrob Chemother; 2013 Jan; 68(1):168-76. PubMed ID: 22966180
[TBL] [Abstract][Full Text] [Related]
8. Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection.
Chilton CH; Crowther GS; Śpiewak K; Brindell M; Singh G; Wilcox MH; Monaghan TM
J Antimicrob Chemother; 2016 Apr; 71(4):975-85. PubMed ID: 26759363
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model.
Baines SD; Chilton CH; Crowther GS; Todhunter SL; Freeman J; Wilcox MH
J Antimicrob Chemother; 2013 Aug; 68(8):1842-9. PubMed ID: 23557928
[TBL] [Abstract][Full Text] [Related]
10. Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model.
Chilton CH; Freeman J; Crowther GS; Todhunter SL; Nicholson S; Wilcox MH
J Antimicrob Chemother; 2012 Apr; 67(4):951-4. PubMed ID: 22279183
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure.
Chilton CH; Crowther GS; Freeman J; Todhunter SL; Nicholson S; Longshaw CM; Wilcox MH
J Antimicrob Chemother; 2014 Feb; 69(2):451-62. PubMed ID: 24003182
[TBL] [Abstract][Full Text] [Related]
12. Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model.
Crowther GS; Chilton CH; Todhunter SL; Nicholson S; Freeman J; Baines SD; Wilcox MH
J Antimicrob Chemother; 2014 Aug; 69(8):2137-47. PubMed ID: 24788662
[TBL] [Abstract][Full Text] [Related]
13. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model.
Freeman J; Baines SD; Saxton K; Wilcox MH
J Antimicrob Chemother; 2007 Jul; 60(1):83-91. PubMed ID: 17483547
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model.
Ochsner UA; Bell SJ; O'Leary AL; Hoang T; Stone KC; Young CL; Critchley IA; Janjic N
J Antimicrob Chemother; 2009 May; 63(5):964-71. PubMed ID: 19251726
[TBL] [Abstract][Full Text] [Related]
15. Mixed infection by Clostridium difficile in an in vitro model of the human gut.
Baines SD; Crowther GS; Todhunter SL; Freeman J; Chilton CH; Fawley WN; Wilcox MH
J Antimicrob Chemother; 2013 May; 68(5):1139-43. PubMed ID: 23354280
[TBL] [Abstract][Full Text] [Related]
16. Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production.
Chilton CH; Crowther GS; Ashwin H; Longshaw CM; Wilcox MH
PLoS One; 2016; 11(8):e0161200. PubMed ID: 27556739
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection.
Chilton CH; Crowther GS; Todhunter SL; Nicholson S; Freeman J; Chesnel L; Wilcox MH
J Antimicrob Chemother; 2014 Sep; 69(9):2426-33. PubMed ID: 24816211
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model.
Chilton CH; Crowther GS; Todhunter SL; Ashwin H; Longshaw CM; Karas A; Wilcox MH
J Antimicrob Chemother; 2015 Sep; 70(9):2598-607. PubMed ID: 26078392
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model.
Baines SD; Noel AR; Huscroft GS; Todhunter SL; O'Connor R; Hobbs JK; Freeman J; Lovering AM; Wilcox MH
J Antimicrob Chemother; 2011 Jul; 66(7):1537-46. PubMed ID: 21504940
[TBL] [Abstract][Full Text] [Related]
20. A combination of the probiotic and prebiotic product can prevent the germination of Clostridium difficile spores and infection.
Rätsep M; Kõljalg S; Sepp E; Smidt I; Truusalu K; Songisepp E; Stsepetova J; Naaber P; Mikelsaar RH; Mikelsaar M
Anaerobe; 2017 Oct; 47():94-103. PubMed ID: 28465256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
